Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and the Risk of Age-Related Macular Degeneration

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and the Risk of Age-Related Macular Degeneration: A Comprehensive Review

Executive Summary

This report offers a thorough examination of the current scientific understanding regarding the relationship between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) and the risk of Age-Related Macular Degeneration (AMD). It integrates existing evidence, explores hypothesized biological pathways, addresses methodological considerations, and outlines clinical implications and future research imperatives.

GLP-1 RAs represent a rapidly expanding class of pharmaceuticals, extensively prescribed for the management of type 2 diabetes and obesity. These medications confer substantial systemic advantages, including significant cardiovascular protection and effective weight reduction. However, the available research concerning their impact on AMD risk presents a complex and, at times, contradictory picture. One notable retrospective cohort study indicates a two-fold elevated risk of neovascular AMD (nAMD) in diabetic patients receiving GLP-1 RAs, with this risk increasing with prolonged exposure. Conversely, another retrospective investigation suggests that GLP-1 RAs may actually diminish the risk of both nonexudative and exudative AMD, potentially attributable to their anti-inflammatory and neuroprotective attributes.   

It is important to contextualize these findings: despite the reported relative increase in risk, the absolute incidence of nAMD within the studied populations remains low, ranging from 0.1% to 0.2%. Proposed mechanisms for an increased risk include the rapid reduction in blood glucose levels potentially leading to retinal hypoxia, while protective effects are theorized to arise from the anti-inflammatory and anti-apoptotic pathways modulated by these agents. The current body of evidence is predominantly derived from observational studies, which can establish associations but not definitive causality, and are inherently susceptible to confounding variables such as the underlying conditions of diabetes and obesity. Therefore, clinical guidance emphasizes an individualized assessment of the risk-benefit profile, particularly for patients with pre-existing AMD risk factors, and underscores the importance of consistent ocular monitoring and pharmacovigilance. Robust prospective studies are essential for drawing more conclusive determinations.   

1. Introduction to Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs)

1.1. Mechanism of Action and Primary Therapeutic Indications

Glucagon-like peptide-1 (GLP-1) receptor agonists, also referred to as GLP-1 analogs or incretin mimetics, represent a class of pharmacological agents designed to emulate the actions of the naturally occurring incretin hormone GLP-1, which is released by the gut following food consumption. These medications exert their therapeutic effects by activating the GLP-1 receptor, initiating a complex cascade of physiological responses.   

The fundamental mechanism of action for GLP-1 RAs involves several key processes. They effectively slow gastric emptying, thereby moderating the rate at which nutrients enter the bloodstream. Concurrently, they inhibit the release of glucagon, a hormone that typically elevates blood sugar levels, and stimulate the production of insulin in a glucose-dependent manner. This coordinated action significantly enhances glucose homeostasis, leading to improved blood sugar control and a reduced risk of hyperglycemia in individuals with type 2 diabetes. Beyond their glycemic effects, GLP-1 RAs are also highly effective in reducing food intake, fostering a negative energy balance, and consequently promoting substantial body weight reduction over time.   

Initially developed and approved for the treatment of type 2 diabetes, GLP-1 RAs have rapidly become a cornerstone of contemporary diabetes management. The 2022 American Diabetes Association standards of medical care advocate for their use as a first-line therapy for type 2 diabetes, particularly in patients who also present with atherosclerotic cardiovascular disease or obesity. Furthermore, the efficacy of some GLP-1 RAs in promoting weight loss has led to their approval for the treatment of obesity and other components of metabolic syndrome, even in individuals without a diabetes diagnosis. Prominent examples within this class include semaglutide, dulaglutide, liraglutide, exenatide, and tirzepatide.   

The widespread adoption and expanding indications of GLP-1 RAs underscore their growing impact on public health. These medications are experiencing rapid and broad uptake across diverse patient populations, as evidenced by their designation as a first-line therapy for specific diabetes patients and their expanded use for obesity management. The substantial and increasing Medicare expenditures on these drugs further illustrate their significant market penetration.This extensive and growing exposure of a vast number of individuals to GLP-1 RAs means that even rare or previously unrecognized long-term adverse effects, such as potential ocular complications, could ultimately affect a considerable absolute number of patients globally. This widespread use elevates the urgency and importance of comprehensively understanding their complete safety profile, moving beyond initial trial data to robust real-world pharmacovigilance. The rapid market acceptance of GLP-1 RAs highlights the continuous need for post-marketing surveillance and dedicated safety studies to ensure that the long-term assessment of benefits versus risks remains favorable as more varied patient populations receive these therapies.   

1.2. Established Systemic Benefits and Common Adverse Effects

GLP-1 RAs offer a broad spectrum of well-established systemic benefits that extend beyond their primary roles in glycemic control and weight management. Retrospective cohort studies involving over two million individuals have indicated that GLP-1 RAs may reduce the risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimer's disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses, and various respiratory conditions. They are particularly recognized for their cardioprotective effects, contributing to a reduced risk of heart disease and stroke in individuals with diabetes, a benefit thought to be mediated by direct actions on the heart and blood vessels. Research also suggests that GLP-1 RAs may possess neuroprotective properties, potentially safeguarding nerve cells in the brain from damage. Furthermore, these agents exhibit potent anti-inflammatory and anti-apoptotic characteristics and have been associated with lower all-cause mortality in patients with type 2 diabetes. A notable advantage is their low propensity for inducing hypoglycemia compared to many other antidiabetic medications.   

Despite these significant advantages, GLP-1 RAs are associated with a range of common adverse effects, predominantly affecting the gastrointestinal system. Nausea, vomiting, diarrhea, and constipation are frequently reported, and these symptoms often dictate the maximum tolerated dose, necessitating a gradual dose escalation strategy. Other reported risks include hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis, and drug-induced pancreatitis. Real-world data indicate high discontinuation rates, with 20% to 50% of patients stopping treatment within the first year, frequently due to these side effects or the substantial cost of the medications.Additionally, the delayed gastric emptying mechanism of action, while beneficial for glucose control, may increase the risk of aspiration during anesthesia, prompting clinical guidelines for withholding the medication prior to surgical procedures.   

The established systemic benefits of GLP-1 RAs are substantial and often critical for patients managing diabetes and obesity. When new, less common, or potentially serious adverse events, such as ocular complications like AMD, emerge from post-marketing surveillance or observational studies, clinicians face a complex decision-making process. They must carefully weigh these emerging signals against the well-established and often life-saving systemic advantages of the drug. The current medical understanding, as indicated in the available literature, suggests that GLP-1 RA use should generally not be discouraged in most patients due to their proven systemic benefits, but with a recommendation for increased ophthalmologic monitoring. This position implies that the perceived absolute risk of these new ocular complications is currently considered low relative to the overall health improvements afforded by treating the underlying metabolic conditions. This ongoing re-evaluation of the risk-benefit profile is a dynamic and essential aspect of pharmacovigilance, illustrating how drug safety knowledge evolves as real-world data from diverse patient populations accumulates beyond the controlled environment of initial clinical trials. This continuous learning process is fundamental for informing clinical guidelines and patient counseling.   

2. Understanding Age-Related Macular Degeneration (AMD)

2.1. Pathophysiology and Clinical Manifestations

Age-related macular degeneration (AMD) is a progressive neuroinflammatory condition that stands as the leading cause of severe, irreversible vision loss among individuals aged 50 and older in developed nations. This debilitating disease specifically targets the macula, a small, highly specialized region at the center of the retina. The macula is indispensable for sharp, detailed central vision, which is critical for everyday activities such as reading, driving, and recognizing faces.   

The pathogenesis of AMD is multifaceted, involving intricate interactions between genetic predispositions and environmental factors. It is fundamentally characterized by heightened oxidative stress and chronic inflammation within the retinal tissues. In its advanced stages, particularly the neovascular form, AMD is further associated with retinal hypoxia, exacerbation of oxidative stress, dysregulation of lipid metabolism, and persistent inflammatory processes.   

Clinically, AMD presents with a range of symptoms that primarily impair central vision, while peripheral vision typically remains unaffected. Patients may report blurred or fuzzy vision, difficulty adapting to low light conditions, altered perception of colors, and a characteristic distortion where straight lines appear wavy or curved. As the disease progresses, dark or blank spots may emerge in the central field of vision, making it challenging to recognize familiar faces or read small print. An early diagnostic indicator is the presence of tiny yellow protein deposits, known as drusen, located beneath the macula. While AMD rarely results in total blindness, the profound loss of central vision can significantly compromise an individual's quality of life and independence.   

The understanding of AMD as a systemic disease manifestation is crucial for evaluating its relationship with systemic medications. AMD is described as a "multifactorial disorder" influenced by "systemic health factors" and characterized by "oxidative stress and chronic inflammation". Its pathogenesis also involves "hypoxia". This systemic connection is profoundly significant when considering the effects of medications like GLP-1 RAs. Given that GLP-1 RAs are known to exert anti-inflammatory and neuroprotective effects , it is biologically plausible that they could influence AMD progression by modulating these systemic inflammatory and oxidative pathways. Conversely, the hypothesis that rapid glucose lowering by GLP-1 RAs might induce retinal hypoxia highlights a potential detrimental systemic-ocular link, where a beneficial metabolic change (glucose reduction) could inadvertently trigger a localized adverse ocular event due to the retina's unique metabolic sensitivity. This understanding reinforces the need for a holistic approach to patient care, where systemic treatments for conditions like diabetes and obesity should consider their potential, sometimes unexpected, impacts on ocular health. It also suggests that managing underlying systemic metabolic and inflammatory conditions is a critical strategy for AMD prevention and management.   

2.2. Types, Stages, and Established Risk Factors

AMD is primarily classified into two main types: dry and wet, each characterized by distinct pathological processes and clinical courses.

• Dry (Atrophic) Macular Degeneration: This form is the most prevalent, accounting for approximately 90% of all AMD cases. It arises from the accumulation of tiny yellow protein deposits, known as drusen, beneath the macula. These deposits lead to the gradual thinning and drying of the macula tissue. Vision loss associated with dry AMD typically progresses slowly and gradually, and most individuals do not experience complete loss of central vision, although it can transition into the more severe wet form in some instances. Dry AMD typically progresses through three stages: Early (macular changes are present but vision is unaffected), Intermediate (vision may become blurry or wavy), and Late/Advanced (characterized by complete central vision failure).   
• Wet (Exudative or Neovascular) Macular Degeneration (nAMD): Although less common, affecting approximately 10% of AMD patients, wet AMD is considerably more severe and is responsible for about 90% of the severe vision loss associated with the disease. This type is distinguished by the abnormal growth of fragile new blood vessels (neovascularization) beneath the retina and macula. These aberrant vessels are prone to leaking blood and fluid, which causes a bulge in the macula and can lead to rapid and permanent central vision loss. Wet AMD is inherently considered an advanced stage of the disease at its onset.   

Several factors contribute to the development and progression of AMD. The most significant non-modifiable risk factor is advanced age, with the probability of developing AMD increasing markedly after 50 years of age. Other non-modifiable risk factors include a family history of AMD and being of white ethnicity. Modifiable lifestyle and systemic health factors also play a crucial role:   

• Smoking: This is a major modifiable risk factor, substantially increasing the risk of AMD by two to three times.   
• Obesity/Being Overweight: These conditions are associated with an elevated risk of both early and late AMD, with abdominal obesity being a particular concern. Research suggests that a history of obesity can contribute to AMD risk even after weight loss, potentially due to lasting changes in the immune system and fat tissue signaling.   
• High Blood Pressure (Hypertension): A recognized risk factor for AMD.   
• Diet: A diet rich in saturated fats is linked to an increased risk, whereas adherence to a Mediterranean diet (characterized by high consumption of fruits, vegetables, whole grains, nuts, and omega-3 fatty acids) may lower the risk.   
• Diabetes Mellitus: While diabetic retinopathy is a distinct ocular complication, diabetes itself is considered a risk factor for AMD, particularly for its late stages. However, some studies propose that diabetic retinopathy, rather than diabetes alone, may be the independent risk factor for dry AMD.   

The patient population receiving GLP-1 RAs inherently carries a higher baseline susceptibility to AMD due to their underlying metabolic diseases. Diabetes and obesity are unequivocally established as significant risk factors for AMD , and GLP-1 RAs are predominantly prescribed to patients diagnosed with these very conditions. This pre-existing elevated risk complicates the interpretation of studies investigating GLP-1 RA effects on AMD. It raises a crucial question: is any observed change in AMD incidence a direct effect of the drug, or is it a modification of the already heightened risk profile of the underlying disease? For example, the Toronto study's finding of increased nAMD risk specifically in diabetic patients on GLP-1 RAs is particularly pertinent, as these individuals are already prone to ocular complications. The nuanced discussion regarding whether diabetes itself or its complication, diabetic retinopathy, is the primary independent risk factor for AMD further emphasizes the need for meticulous control of confounding variables in research. This situation highlights the critical importance of rigorous study design, including comprehensive propensity matching and adjustment for a multitude of comorbidities and disease severities, when evaluating drug safety in populations with complex, intertwined risk factors. Clinically, it underscores the necessity of a thorough baseline ocular assessment for individuals with diabetes and/or obesity before initiating GLP-1 RA therapy, and continued vigilance throughout treatment.   

3. The Interplay: GLP-1 RAs and Age-Related Macular Degeneration Risk

3.1. Evidence Suggesting an Increased Risk of Neovascular AMD

A recent and highly impactful retrospective cohort study, published in JAMA Ophthalmology on June 5, 2025, by researchers at the University of Toronto, has identified a potential association between the use of GLP-1 RAs and an elevated risk of neovascular Age-Related Macular Degeneration (nAMD).   

Methodology: This large-scale investigation utilized health data from Ontario, Canada, analyzing a cohort of 139,002 diabetic patients aged 66 years or older. All participants had a minimum of 12 months of follow-up after their initial diabetes diagnosis. To minimize the influence of confounding factors, a 1:2 propensity-matched cohort was created, comprising 46,334 patients exposed to GLP-1 RAs for at least six months and 92,668 unexposed matched patients. The matching process meticulously accounted for sociodemographic characteristics and various medical comorbidities. The study tracked patient outcomes over a three-year follow-up period, specifically from 2020 to 2023.   

Key Findings:

• The study reported that diabetic patients who were prescribed GLP-1 RAs were found to be twice as likely to develop nAMD compared to their unexposed diabetic counterparts (adjusted Hazard Ratio 2.21; 95% CI, 1.65-2.96).   
• Despite this significant relative risk, the absolute incidence of nAMD remained low: 0.2% (93 patients) in the GLP-1 RA user group compared to 0.1% (88 patients) in the unexposed group.   
• A particularly noteworthy finding was the observed dose-response relationship: the risk of developing nAMD increased proportionally with the duration of GLP-1 RA exposure. Specifically, patients who took GLP-1 RAs for 18-30 months experienced more than double the risk, and those on the drugs for 30 months or longer faced more than triple the risk compared to non-users.   
• The vast majority (97.5%) of GLP-1 RA users in this cohort were prescribed semaglutide, which is marketed under brand names such as Ozempic, Wegovy, and Rybelsus, while the remaining 2.5% took lixisenatide.   

The observed dose-response effect, where increased cumulative exposure to the drug correlates with an increased risk of the outcome, is a strong indicator. The Toronto study explicitly states that "the risk became even higher for those who were on GLP-1s the longest" and that "longer durations of exposure to GLP-1 RAs were associated with a higher risk of nAMD, with more than three times the risk among those with the longest exposure". In epidemiological studies, such a relationship is considered a more robust signal of a potential biological effect compared to a simple binary association (exposed vs. unexposed). As acknowledged by a study co-author, this finding "strengthens the argument that this association may reflect a true biological effect rather than being due to confounding factors". While this does not definitively prove causation, given the observational nature of the study, it lends significant weight to the observed link and warrants serious, targeted investigation into the underlying biological mechanisms. This specific finding necessitates a more cautious approach to long-term GLP-1 RA use, particularly in patients who may already have pre-existing risk factors for AMD or early signs of the disease. It also strongly suggests that future prospective research should meticulously track and analyze cumulative dose and duration of exposure as key variables when assessing ocular safety.   

Related Ocular Concerns: These findings contribute to a growing body of literature raising concerns about the ocular safety of systemic GLP-1 RA use. Previous research has also linked semaglutide to a potential risk factor for nonarteritic anterior ischemic optic neuropathy (NAION), a serious eye condition characterized by vision loss due to decreased blood supply to the optic nerve. The European Medicines Agency (EMA) has initiated a review of this potential safety risk.   

Table 1: Key Findings from the University of Toronto Study on Increased nAMD Risk with GLP-1 RAs

Feature	Details
Study/Publication	University of Toronto / JAMA Ophthalmology (June 5, 2025)
Study Design	Retrospective Cohort Study
Patient Population	N=139,002 diabetic patients (46,334 exposed, 92,668 unexposed), aged 66+ years, in Ontario, Canada
Primary GLP-1 RA	Semaglutide (97.5% of exposed group)
Follow-up Period	Approximately 3 years (2020-2023)
Key Outcome (nAMD Incidence)	0.2% in GLP-1 RA users vs. 0.1% in non-users
Hazard Ratio (HR) with 95% CI	Adjusted HR 2.21 (95% CI, 1.65-2.96)
Dose-Response Effect	Risk increased with longer duration of exposure (e.g., >30 months, risk more than tripled)
Key Takeaway	GLP-1 RA use associated with a two-fold higher relative risk of nAMD in diabetic patients, with risk increasing with duration of use, though absolute risk remains low.

 

3.2. Evidence Suggesting Potential Protective Effects on AMD and Ocular Health

In contrast to the findings suggesting an increased risk, another significant retrospective cohort study from the Case Western Reserve University School of Medicine, published in Ophthalmology on January 23, 2025, investigated the potential influence of GLP-1 RAs on the risk of various age-related ocular diseases, including AMD.   

Methodology: This study leveraged an electronic health records platform encompassing patients within the United States. It included 9,669 patients who were prescribed GLP-1 RAs, with a substantial majority (84.4%) having a diagnosis of diabetes and an average body mass index (BMI) of 36.2 kg/m2. Participants were over 60 years of age and had at least 5 years of ophthalmology follow-up and documented medication prescriptions. The researchers meticulously created propensity-matched cohorts (1:1) for comparison across five distinct medication groups: GLP-1 RA users, metformin users, insulin users, statin users, or aspirin users. The primary outcomes assessed included the incidence of cataract, ocular hypertension, primary open-angle glaucoma (POAG), nonexudative AMD, and exudative AMD, compared over a 5-year period.   

Key Findings:

• Propensity-matched cohorts demonstrated that GLP-1 RAs were associated with a reduced hazard of nonexudative AMD. This reduction was statistically significant when compared to metformin (HR, 0.68; 95% CI, 0.56-0.84), insulin (HR, 0.72; 95% CI, 0.58-0.89), and statins (HR, 0.70; 95% CI, 0.57-0.87). This significant reduction in risk became apparent after 3 years of medication use.   
• Importantly, GLP-1 RAs also significantly reduced the risk of exudative AMD (HR, 0.70; 95% CI, 0.58-0.84) and primary open-angle glaucoma (HR, 0.58; 95% CI, 0.45-0.76) when compared to insulin after 3 years.   
• The study found no persistent significant impact of GLP-1 RA use on the risk of cataract formation or ocular hypertension when compared with other medications.   

The anti-inflammatory/neuroprotective hypothesis provides a plausible explanation for the observed protective ocular effects. The Case Western study found protective effects against both dry and wet AMD. Multiple sources highlight GLP-1 RAs' neuroprotective and anti-inflammatory properties across various organ systems. These observed protective ocular effects align with the known pleiotropic (multiple, diverse) beneficial actions of GLP-1 RAs beyond glucose regulation. Given that inflammation and oxidative stress are recognized as key drivers in the pathogenesis of AMD , the anti-inflammatory and anti-apoptotic properties of GLP-1 RAs could directly counteract these pathological processes within the retina, thereby reducing AMD risk or slowing its progression. Furthermore, experimental studies support that GLP-1 RAs may prevent or slow the progression of diabetic retinopathy through anti-inflammatory and anti-apoptotic pathways. This hypothesis introduces a critical counterpoint to the "rapid glycemic control leading to hypoxia" theory. It suggests that GLP-1 RAs might exert a dual influence on ocular health, with potential long-term protective effects mediated by their anti-inflammatory actions, which could eventually outweigh or modulate any acute detrimental effects from rapid metabolic shifts. This complexity underscores the need for research to differentiate between acute and chronic effects and to explore the net impact of these competing pathways.   

Table 2: Key Findings from the Case Western Reserve University Study on Protective Ocular Effects of GLP-1 RAs

Feature	Details
Study/Publication	Case Western Reserve University School of Medicine / Ophthalmology (Jan 23, 2025)
Study Design	Retrospective Cohort Study
Patient Population	N=9,669 GLP-1 RA users (>60 years, 84.4% diabetic, avg. BMI 36.2 kg/m2), US electronic health records
Comparators	Metformin, Insulin, Statins, Aspirin
Follow-up Period	5 years (significant reduction observed after 3 years)
Key Outcomes (Hazard Ratios)	Nonexudative AMD: HR 0.68 (vs. metformin), HR 0.72 (vs. insulin), HR 0.70 (vs. statins)
	Exudative AMD: HR 0.70 (vs. insulin)
	Primary Open-Angle Glaucoma: HR 0.58 (vs. insulin)
	No significant impact on cataract or ocular hypertension
Key Takeaway	GLP-1 RA use associated with a reduced hazard of both nonexudative and exudative AMD, and primary open-angle glaucoma, suggesting potential protective effects.

 

3.3. Proposed Biological Mechanisms: Detrimental vs. Protective Pathways

The conflicting clinical observations regarding the association between GLP-1 RAs and AMD risk necessitate a detailed exploration of the underlying biological mechanisms that could contribute to both detrimental and protective pathways.

Detrimental Hypothesis (Retinal Hypoxia): One prominent hypothesis for the observed increased risk of nAMD, particularly in the context of rapid glycemic control, centers on the concept of retinal hypoxia. It is theorized that the swift and substantial reduction in blood glucose levels induced by GLP-1 RAs might lead to a sudden metabolic shift within the retina, creating a state of relative oxygen deprivation, or hypoxia. This hypoxic environment is a well-established stimulus for angiogenesis, the abnormal growth of new blood vessels that is a hallmark of wet AMD. This phenomenon, where rapid glucose lowering can paradoxically worsen retinopathy, has been observed in other clinical contexts, particularly in diabetic retinopathy. The retina, being a highly metabolically active tissue, is particularly sensitive to abrupt changes in glucose and oxygen supply, making it vulnerable to such a mechanism.   

Protective Hypothesis (Anti-inflammatory and Neuroprotective Effects): Conversely, the proposed protective effects of GLP-1 RAs on AMD are rooted in their broader pleiotropic actions. GLP-1 RAs are well-documented to exert significant neuroprotective and anti-inflammatory effects across various organ systems, including the brain and cardiovascular system. Given that chronic inflammation and oxidative stress are recognized as key pathological drivers in the development and progression of AMD , these anti-inflammatory and anti-apoptotic properties could directly counteract the degenerative processes within the retina, thereby potentially reducing AMD risk or slowing its progression. Experimental studies have further demonstrated that GLP-1 RAs may prevent the onset or dampen the progression of diabetic retinopathy through anti-inflammatory and anti-apoptotic pathways. The presence of GLP-1 receptors in neuronal cells of the human eye also provides a biological basis for direct ocular effects.   

The co-existence of these two opposing hypotheses highlights the complex biological interplay at play. It is possible that GLP-1 RAs exert both beneficial and potentially detrimental effects on the retina simultaneously, with the net outcome depending on various factors such as the patient's individual metabolic state, the duration and rapidity of glycemic control, the specific GLP-1 RA agent used, and the presence of pre-existing ocular conditions.

4. Discussion: Reconciling Conflicting Evidence and Methodological Considerations

4.1. Confounding Factors and Study Limitations

The conflicting findings regarding GLP-1 RAs and AMD risk underscore the inherent challenges in epidemiological research, particularly when investigating complex interactions in real-world patient populations. Both studies discussed are retrospective cohort studies, which, by their nature, can only establish associations and not definitive causal relationships. While propensity matching and adjustment for various comorbidities were employed to mitigate confounding, residual confounding remains a significant limitation.   

One critical confounding factor is the underlying conditions for which GLP-1 RAs are prescribed: type 2 diabetes and obesity. Both diabetes and obesity are independently recognized as risk factors for AMD. The patient populations receiving GLP-1 RAs already have an elevated baseline risk for AMD due to these metabolic disorders. This makes it challenging to disentangle whether any observed change in AMD incidence is a direct pharmacological effect of the GLP-1 RA or a modification of the pre-existing heightened risk profile of the underlying disease. For example, a commentator on the JAMA Ophthalmology study noted the absence of matching for BMI, which is a known risk factor for AMD progression, suggesting a potential difference in BMI between the exposed and unexposed groups that could influence the findings. The nuanced debate surrounding whether diabetes itself or its complication, diabetic retinopathy, is the primary independent risk factor for AMD further highlights the need for meticulous control of all relevant variables.   

Furthermore, the rapid glucose lowering achieved by GLP-1 RAs has been implicated in the worsening of pre-existing diabetic retinopathy in some instances. This phenomenon, often termed "rapid glycemic control-induced retinopathy," could potentially contribute to or exacerbate other ocular conditions like nAMD, especially in a vulnerable diabetic population. The observational nature of these studies means that factors such as the severity and duration of diabetes, the degree and rapidity of glycemic control achieved, and the presence of undiagnosed early AMD at baseline could influence the results.   

The differences in study populations, comparator groups, and follow-up durations between the JAMA Ophthalmologystudy (focusing on diabetic patients aged 66+ in Canada, primarily semaglutide users) and the Ophthalmology study (US patients >60, 84.4% diabetic, comparing GLP-1 RAs to multiple other drug classes) could also contribute to the divergent findings. The specific GLP-1 RA used, its dosage, and the duration of exposure are also crucial variables that require further investigation, particularly given the dose-response effect observed in the JAMA Ophthalmology study.   

4.2. Current Consensus and Clinical Implications

Given the conflicting evidence and methodological limitations of current research, a definitive consensus on the precise relationship between GLP-1 RAs and AMD risk has not yet been established. The current understanding suggests a complex interplay of factors where GLP-1 RAs may exert both protective and potentially detrimental effects on ocular health.

From a clinical perspective, the proven systemic benefits of GLP-1 RAs in managing type 2 diabetes, obesity, and reducing cardiovascular risk are substantial and often critical for patient health. Therefore, the general medical position is that GLP-1 RA use should not be broadly discouraged based on the current ocular safety signals alone.   

However, the emerging data, particularly the JAMA Ophthalmology study's findings of an increased relative risk of nAMD with longer exposure, necessitate heightened clinical vigilance. Clinicians should be aware of the potential for ocular complications associated with GLP-1 RA use and are encouraged to report any suspected adverse events to post-marketing pharmacovigilance systems to facilitate safety tracking and raise public awareness.   

For patients with diabetes, especially those who are older or have pre-existing risk factors for AMD (e.g., family history, smoking, obesity, hypertension), a thorough baseline ocular assessment before initiating GLP-1 RA therapy is advisable. Regular, annual eye examinations are already recommended for individuals with diabetes to monitor for diabetic retinopathy and other ocular conditions. This recommendation becomes even more pertinent for those on GLP-1 RAs. Patients should be educated about the signs and symptoms of vision changes, such as blurred vision, distorted straight lines, or central blind spots, and advised to consult an eye care provider immediately if these symptoms arise.   

5. Conclusion and Future Research Directions

The relationship between Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular Degeneration risk is a dynamic and evolving area of research, characterized by seemingly contradictory findings. While GLP-1 RAs offer profound systemic benefits for diabetes and obesity management, including cardiovascular and neuroprotective effects, recent observational studies present a bifurcated view on their ocular safety profile. One significant study indicates a two-fold increased relative risk of neovascular AMD in diabetic patients on GLP-1 RAs, with risk escalating with prolonged exposure, though the absolute incidence remains low. Conversely, another study suggests potential protective effects against both dry and wet AMD, possibly mediated by the anti-inflammatory and neuroprotective properties of these agents.

The proposed biological mechanisms reflect this complexity: rapid glucose lowering may induce retinal hypoxia, potentially promoting nAMD, while the inherent anti-inflammatory and anti-apoptotic actions of GLP-1 RAs could offer protective benefits. Reconciling these observations requires acknowledging the limitations of retrospective studies, particularly the challenge of definitively establishing causality and controlling for all confounding factors, such as the pre-existing elevated AMD risk in diabetic and obese populations.

Moving forward, robust prospective studies are indispensable to definitively clarify the long-term ocular safety profile of GLP-1 RAs. Future research should:

• Conduct large-scale, prospective, randomized controlled trials designed with ocular endpoints to provide higher-level evidence.
• Investigate specific GLP-1 RA agents to determine if differences exist in their ocular safety profiles.
• Explore the dose-dependent effects of GLP-1 RAs on AMD, differentiating between doses used for diabetes versus obesity.
• Elucidate the precise biological mechanisms that mediate both potential detrimental and protective effects on retinal health, possibly through preclinical and translational studies.
• Assess the impact of the rapidity and magnitude of glycemic control on ocular outcomes.

Until more definitive evidence emerges, clinicians should continue to prescribe GLP-1 RAs based on their well-established systemic benefits, while maintaining a heightened awareness of potential ocular complications. Individualized risk-benefit assessments, comprehensive baseline ocular evaluations, and vigilant ongoing monitoring, particularly for patients with pre-existing AMD risk factors, are paramount to optimize patient care. The continuous process of pharmacovigilance and open reporting of suspected adverse events will remain crucial in refining the understanding of GLP-1 RAs' full safety spectrum.

References

1. Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity, cardiovascular protection, weight reduction.   
2. Retrospective cohort study on GLP-1 RAs and substance use, psychotic disorders, seizures, neurocognitive disorders, coagulation disorders, cardiometabolic disorders, infectious illnesses, respiratory conditions, gastrointestinal disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis, and drug-induced pancreatitis.   
3. GLP-1 RAs for type 2 diabetes and obesity, cardiovascular protection, weight reduction, and Medicare expenditures.   
4. GLP-1 RAs for type 2 diabetes and obesity, cardiovascular protection, weight reduction, neuroprotective properties, anti-inflammatory, anti-apoptotic, low hypoglycemia risk.   
5. GLP-1 RAs for type 2 diabetes and obesity, cardiovascular protection, weight reduction, lower all-cause mortality.   
6. University of Toronto study on GLP-1 RAs and increased nAMD risk in diabetic patients.   
7. Age-related macular degeneration (AMD) as leading cause of vision loss, affects macula, symptoms, nAMD linked to hypoxia, oxidative stress, lipid metabolism, inflammation.   
8. University of Toronto study co-author comment on dose-response effect strengthening biological link, caution against extended use, annual eye exams.   
9. University of Toronto study on GLP-1 RAs and increased nAMD risk, dose-response, semaglutide, and potential for worsening diabetic retinopathy.   
10. Case Western Reserve University study on GLP-1 RAs and reduced risk of nonexudative and exudative AMD, and POAG.   
11. GLP-1 RAs potential protective effects against glaucoma, AMD, DED due to anti-inflammatory properties; general consensus not to discourage use but recommend ophthalmologic follow-up.   
12. GLP-1 RAs should generally not be discouraged, but with increased ophthalmologic monitoring.   
13. GLP-1 RAs mechanism of action: slow gastric emptying, inhibit glucagon, stimulate insulin, reduce food intake, weight reduction.   
14. High discontinuation rates of GLP-1 RAs due to side effects (nausea, vomiting, diarrhea, constipation) and cost.   
15. Medicare expenditures on GLP-1 RAs.   
16. GLP-1 RAs common adverse effects: gastrointestinal, hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis, drug-induced pancreatitis.   
17. AMD pathophysiology, central vision loss, blurred/fuzzy vision, distorted lines, dark spots, drusen.   
18. AMD as neuroinflammatory condition, oxidative stress, chronic inflammation.   
19. Obesity/being overweight as AMD risk factor, abdominal obesity, history of obesity.   
20. AMD types (dry, wet), stages (early, intermediate, late dry; wet is advanced), risk factors (age, family history, white ethnicity, smoking, obesity, hypertension, diet, diabetes).   
21. AMD risk factors: age, genetic predispositions, environmental factors, smoking, obesity, hypertension, diet.   
22. Retinal hypoxia as a stimulus for angiogenesis in wet AMD.   
23. Diabetes as a risk factor for AMD, particularly late stages.   
24. Diabetic retinopathy as an independent risk factor for dry AMD.   
25. GLP-1 RAs linked to potential risk of nonarteritic anterior ischemic optic neuropathy (NAION).   
26. GLP-1 receptors detected in neuronal cells of the human eye.